Panelists discuss how the pathophysiology of pulmonary arterial hypertension involves complex mechanisms across multiple genetic and treatment pathways, with over 20 identified genes and four major ...

Pulmonary arterial hypertension (PAH) is a devastating disease characterized by arteriopathy in the small to medium-sized distal pulmonary arteries, often accompanied by infiltration of inflammatory ...

A drug prototype known as NZ-97 showed promise for treating pulmonary disease by stimulating growth of new stem cells to repair damaged tissue, based on data from a new proof-of-concept study. In many ...

Cell-cell interactions via proteins and ligand-receptor interactions contribute to PF pathogenesis. Single-cell RNA genome sequencing technique and bio-informatics oriented approaches combined with ...

PF pathogenesis involves alveolar epithelial cell injury, profibrotic mediators, and dysregulated non-coding RNAs, complicating disease management. Current treatments, including pirfenidone and ...